Shanghai, China – April 30, 2015 – Two medical devices of Shanghai MicroPort Medical (Group) Co ("MicroPort") - Firehawk® Rapamycin Target Eluting Coronary Stent System and WILLIS® Intracranial Stent Graft System - were proved to have relatively high cost-effectiveness, according to official health economic evaluation results recently released.
On April 24, experts announced the health economic evaluation results of Firehawk® and WILLIS®, products respectively developed by MicroPort and its subsidiary MicroPort NeuroTech (Shanghai) Co, in an experience-sharing meeting on centralized procurement of disposable medical supplies, organized by China Association of Medical Equipment.
During the meeting, Dr. Xiaohua Ying, Professor of Public Health School of Fudan University and Deputy Director of Key Lab of Health Technology Assessment of Ministry of Health, shared the evaluation results of Firehawk®. Specifically, Firehawk® has better therapeutic effect in treating patients with single coronary artery lesion in single vessel, compared to imported stents of the same price. Besides, in treating patients with single coronary artery lesion in single vessel, as long as Firehawk®'s price is no higher than 113% of the imported stents, every unit of incremental cost of Firehawk® brings more additional unit of the measure of effect.
Meanwhile, Dr. Jianwei Xuan, Professor of Florida State University, Advisory Professor of Public Health School of Fudan University, Research Fellow of the Research Center of National Drug Policy & Ecosystem, and President of Advisory Committee of Asia-Pacific Branch of International Society for Pharmacoeconomics and Outcomes Research, explained the assessment results of WILLIS®. It showed, compared with coil embolization treatment, WILLIS® has higher clinical efficacy and lower overall cost.
In the future, health economic evaluation will provide important decision rules for China's pricing and purchasing policies. Unlike traditional assessment methods that only focus on the safety and effectiveness of a medical product, health economic studies evaluate both cost and effects, which better serve to guide optimal healthcare resource allocation.